[Cardiac arrhythmias in patients with chronic kidney disease]

Area of Science:

• Nephrology
• Cardiology
• Clinical Trials

Background:

• Chronic kidney disease (CKD) significantly increases cardiovascular risks, notably supraventricular and ventricular arrhythmias.
• Pathomechanisms involve atrial and ventricular fibrosis, leading to cardiac remodeling in CKD patients.
• Limited clinical trial data for advanced CKD hinders specific arrhythmia treatment guidelines.

Purpose of the Study:

• To review current understanding of cardiac arrhythmia management in advanced chronic kidney disease.
• To highlight challenges and considerations for treating arrhythmias in this patient population.

Main Methods:

• Literature review of studies concerning CKD, cardiovascular disease, and arrhythmias.
• Analysis of treatment modalities including implantable cardioverter defibrillators (ICDs), anticoagulation, antiarrhythmic drugs, and pulmonary vein isolation.

Main Results:

• Individualized assessment is crucial for ICD therapy and anticoagulation in advanced CKD.
• Antiarrhythmic drug dosages may require adjustment based on renal function and metabolism.
• Pulmonary vein isolation for atrial fibrillation shows reduced efficacy in advanced CKD patients.

Conclusions:

• A personalized therapeutic strategy is essential for managing cardiac arrhythmias in patients with advanced CKD.
• Careful consideration of comorbidities, prognosis, and pharmacokinetic changes is necessary.
• Further research is needed to establish evidence-based guidelines for arrhythmia management in CKD.